Ajanta Pharma Limited (NSE:AJANTPHARM)
2,969.00
+11.20 (0.38%)
Feb 18, 2026, 12:10 PM IST
Ajanta Pharma Revenue
Ajanta Pharma had revenue of 13.75B INR in the quarter ending December 31, 2025, with 19.95% growth. This brings the company's revenue in the last twelve months to 52.02B, up 14.78% year-over-year. In the fiscal year ending March 31, 2025, Ajanta Pharma had annual revenue of 46.48B with 10.44% growth.
Revenue (ttm)
52.02B
Revenue Growth
+14.78%
P/S Ratio
7.10
Revenue / Employee
5.40M
Employees
9,628
Market Cap
369.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Ipca Laboratories | 95.06B |
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Laurus Labs | 67.22B |
Ajanta Pharma News
- 15 days ago - Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 15 days ago - Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript - GuruFocus
- 19 days ago - Pharma sector stocks today, Jan 30: Aurobindo Pharma jumps 3%, Ajanta Pharma up 2%, Natco Pharma rises 2% - Business Upturn
- 5 weeks ago - India’s Ajanta Pharma eyes Irish manufacturing base - Independent Ireland
- 2 months ago - Ajanta Pharma shares jump over 4% after signing in-licensing agreement with Biocon - Business Upturn
- 2 months ago - Biocon signs out-licensing deal with Ajanta Pharma to market Semaglutide in overseas markets - Business Upturn
- 3 months ago - Bharti Airtel, Titan & more: Top stocks on brokers' radar today - The Times of India
- 3 months ago - Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ... - GuruFocus